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A blood group A glycosphingolipid with the globe-series tructure has been isolated from human kidney 
and structurally characterized. The structure was shown by mass spectrometry and proton NMR spectros- 
copy of the intact permethylated and permethylated-reduced derivatives together with degradation studies 
to be, GalNAccli +3Gal(2c laFuc)~l+3GalNAc/H -r3Galcc1-+4Gal~l -r4Glc/?l-+ 1Ceramide. This glyco- 
lipid reacts with both polyclonal and monoclonal anti-A blood group typing antisera and it is the major 
glycolipid based blood group A antigen present in the human kidney. 
Blood group A Giycolipid 
1. INTRODUCTION 
A large number of blood group A 
glycosphingolipids have been isolated and struc- 
turally characterized from human and animal 
tissues (review [1,2]). Blood group A glycolipids 
present in human tissues are based upon type 
(Gal,& +3GlcNAc) 
fG@l -~G~cNAc) carbohyzzz chaii$ (1,2; 
while other types of core saccharides carrying the 
A trisaccharide have been identified in animal 
tissues [l-3]. This paper describes the structural 
characterization of a novel blood group A hep- 
taglycosylceramide isolated from human blood 
group A kidneys. This glycolipid has the A trisac- 
charide linked ,&l-+3 to the g~actosamine of 
globotetraosylceramide and represents a new type 
of core saccharide based A antigen in human 
The data were presented at the XI&h International Car- 
bohydrate Symposium, Utrecht, The Netherlands, Juty 
1984 
Giobo-series Human kidney 
tissue, When this work was completed, we learned 
that the same compound had been isolated from 
human A1 erythrocytes (S. Hakomori, personal 
communication), 
2. EXPERIMENTAL 
Kidneys were obtained from blood group A 
human individuals at autopsy. The total non-acid 
glycolipid fraction was prepared as in 13-61. The 
major part of the glycolipids with 1-4 sugar 
residues was removed by repeated silicic acid 
chromatography [3] and the polar glycolipid frac- 
tion obtained (fig. 1, lane B) was further separated 
on an Iatrobeads column (Iatron, Tokyo) eluted by 
a continuous gradient of chloroform-methanol- 
water (from 65 :25 :4 to 50:40: 10 followed by a 
final elution with 40: 40: 12, by vol.). After separa- 
tion by thin-layer chromatography, the fractions 
were combined into 8 partly purified fractions for 
structural analysis. The fraction characterized here 
(fig.1, lane C) had a thin-layer mobility as a 
heptaglycosylceramide. 
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The permethylated and permethylated-reduced 
(LiAlH4) intact glycolipid fractions were analysed 
by mass spectrometry [7,8] on a ZAB 2F high 
resolution instrument (VG Instruments) and by 
270 MHz proton NMR spectroscopy [9- 111. 
The carbohydrate composition and sugar 
linkage positions were established by degradation 
of the native, permethylated and permethylated- 
reduced derivatives as in [6,12,13]. The degrada- 
tion products were identified by gas chromatog- 
raphy and gas chromatography-mass spectrome- 
try. Blood group A activity of the native glycolipid 
fraction was tested by hemagglutination-inhibition 
[14] using a commercial human polyclonal anti-A 
antiserum (Biol. Corp., West Chester). The re- 
activity against a mouse monoclonal anti-A anti- 
body (Biotest, Frankfurt) was tested by immuno- 
staining on the thin-layer plate [15,16]. 
3. RESULTS 
The weight of the total non-acid glycolipid frac- 
tion (fig. 1, lane A) isolated from the human blood 
group A kidneys was 2.9 g corresponding to 
5.6 mg per g dry tissue weight. Tri- and 
tetraglycosylceramides were the major glycolipids 
present together with mono- and diglycosyl- 
ceramides as reported in [17]. In addition, two 
bands were seen migrating as glycolipids having 5 
and 7 sugar residues, respectively. The penta- 
glycosylceramide fraction consisted of 75% of 
globotetraosylceramide with an additional ter- 
minal Gal,&1+3 residue and 25% of the X-5 
glycolipid (type 2 carbohydrate chain isomer of the 
Lewisa pentaglycosylceramide) ([181; to be pub- 
lished). The weight of the heptaglycosylceramide 
fraction (fig. 1, lane C) was 5.5 mg and it contained 
one major component ogether with small amounts 
of tetra- and pentaglycosylceramides. As 
acetylated derivatives, glycolipids sometimes 
change their relative chromatographic migration 
[3,6,12]. Acetylation of the heptaglycosylceramide 
fraction revealed one major band migrating just 
behind globotetraosylceramide and with an iden- 
tical Rf value as a type 1 chain blood group A 
hexaglycosylceramide. 
Mass spectrometry of the permethylated- 
reduced heptaglycosylceramide fraction (fig.2) 
shows a series of intense peaks at m/z 1764-1876 
due to ions containing the whole saccharide chain 
Fig. 1. Thin-layer chromatogram of total non-acid 
glycolipids isolated from kidneys of blood group A 
human individuals (lane A). Lane B shows a polar 
glycolipid fraction obtained from the total fraction. This 
fraction was further separated by gradient elution 
and the fractions containing the heptaglycosylceramide 
were combined (lane C). Reference As-1 glyco- 
lipid GalNAccvl+3Ga1(2+ laFucK?l + 3GlcNAc,&l+ 
3GakTl+4Gl@l+ 1Ceramide (lane D) was from rat 
small intestine [3]. The thin-layer plate was HPTLC, 
Kiselgel 60 (Merck), solvent was chloroform-metha- 
nol-water, 60:35:8 (by vol.), and detection was 
anisaldehyde [4]. 
and 16 : O-24 : 0 non-hydroxy fatty acids. The cor- 
responding fragment for the 24: 0 hydroxy fatty 
acid species is seen at m/z 1906. The ion at m/z 
1838 originates from the hydroxy fatty acid species 
as shown in the formula. Molecular ions for the 
trihydroxy long chain base (t 18 : 0, phytosphingo- 
sine) in combination with 24 : 0 non-hydroxy and 
hydroxy fatty acids are present at m/z 2160 and 
2190, respectively. Primary carbohydrate sequence 
ions are found at m/z 157, 189,246,262,624, 855, 
87 1, 1059 and 1467. Secondary sequence ions con- 
taining the fatty acid and the inner 3 and 4 sugar 
residues are present at m/z 1022 and 1253 for the 
24: 0 non-hydroxy and at m/z 1052 and 1283 for 
the 24: 0 hydroxy fatty acid species, respectively. 
The presence of type 1 or type 2 carbohydrate 
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Fig.2. Mass spectrum and simplified formula for ihterpretation of the permethylated-reduced heptaglycosylceramide 
fraction isolated from human kidney. The conditions of analysis were: sample amount 15 pg, electron energy 45 eV, 
trap current 2OOpA, acceleration voltage 8 kV and ion source temperature 340°C. Peaks below m/e 80 were not 
reproduced. 
chains in glycolipids can be established by mass 
spectrometry [5,7,12,19]. For reduced derivatives, 
a substitution at carbon atom 3 of the hexosamine 
(as for type 1 chains) results in a rearrangement 
ion containing the fatty acid, the inner hexoses 
and part of the hexosamine [19]. In this case, 
corresponding fragments are present at m/z 
1178 (1876 - 624 - 74) and at pn/z 1208 
(1906 - 624 - 74) indicating a substitution at C3 
of the hexosamine. 
In the mass spectrum of the permethylated 
derivative (not shown) primary carbohydrate se- 
quence ions were present at m/z 157, 189 (terminal 
fucose), m/z 228, 260 (terminal hexosamine), m/z 
606, 638 (trisaccharide), m/z 851, 883 (tetrasac- 
charide), m/z 1087 (pentasaccharide), m/z 1291 
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Fig.3. 270-MHz proton NMR spectra of the permethylated (top) and permethylated-reduced (bottom) 
heptaglycosylceramide fraction isolated from human kidney. The amounts of substance analyzed were: (A) 2.5 mg and 
(B) 2.0 mg dissolved in 0.45 ml C’HCI3. (A) 3400 pulses and (B) 4400 pulses at 40°C. 
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(hexasaccharide) and m/z 1568 (complete sac- 
charide chain plus part of the ceramide). Ceramide 
ions were present at m/z 548-660 for dihydroxy 
6 
12 
i, 6 io min 
long chain base (d18 : I, sphingosine) in combina- 
tion with 16: O-24:0 non-hydroxy fatty acids and 
at m/z 692 and 722 for t 18 : 0 base in combination 
with 24:0 non-hydroxy and hydroxy fatty acids, 
respectively. The specific ions for d18 : 1 and t 18 : 0 
bases at m/z 364 and 396 were of equal intensity. 
The mass spectra also revealed the presence of 
small amounts of other glycolipids. The peaks at 
m/z 1590-1702 in fig.2 originate from a blood 
group A hexaglycosylceramide [3]. In spectra 
recorded at lower ion source temperature, 
fragments indicating globotetraosyl-, globopenta- 
osyl- and difucosyl blood group A heptaglyeosyl- 
ceramides were present. In addition, fragments 
originating from the blood group H hexaglycosyl- 
ceramide of the globo-series 1191 were also found. 
These fragments were, however, more intense in 
the spectrum of the hexaglycosylcer~ide fraction 
eluted in front of the heptaglycosylcer~ides on 
the Iatrobeads column (see section 2). The total 
amount of the contaminants was lo-15% as 
calculated from the ion intensities. 
In the proton NMR spectrum of the 
permethylated erivative (fig.3, top), two signals 
from the H-l of the terminal cr-fucose and cy- 
galactosamine are found at 5.39, 5.35 and 
5.2-5.1 ppm, respectively. In the spectrum of the 
reduced derivative (fig.3, bottom) the signal shave 
slid together giving sharp signals at 5.30 ppm for 
the cY-fucose and 5.12 ppm for the cu-galactos- 
amine with small coupling constants (&,z = 2.8 
and 3.3 Hz, respectively). The same phenomena 
have been noted for other blood group A and B 
- 
Fig.4. Gas chromatograms of the products obtained by 
degradation of the permethylated (top) and 
permethylated-reduced (bottom) heptaglycosylceramide 
fraction isolated from human kidney. The identity of the 
peaks was established by mass spectrometry and 
comparison with reference products to be: (1) Fuel -+, 
(2)Gail*, (3) *4Gall-+, (4) +4Gicl-+, (5) -r3Gall-+, 
(6) ~~Gall+, (7) GalNAcl -+, (8) -+4GlcNAcl-*, 
(9) -+3GalNAcld, 
+3Gall-r, 
(10) =jGlcNAcl-+, (11) GalNAcl 
(12) -+3GalNAcl-r3Gall-,, 
=4 
(13) 
+ 4GlcNAc 1 + 3Gall-+ and (14) GlcNAc 1 -+ 
3Gall-+. An open tubular column coated with cross- 
linked nonpolar SE-54 as stationary phase was used. The 
temperature was programmed from 150 to 300°C at a 
rate of 10°C/min. 
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glycolipids [5,10,1 I]. The &signal of the galactose 
linked to the internal galactosamine is found in the 
,&hexose region at 4.30 ppm for the permethylated 
derivative and has moved downfield to 4.59 ppm 
(Jl,z = 8.1 Hz) in the spectrum of the reduced 
derivative. A similar downfield shift is found in 
spectra of glycolipids based on type I carbohydrate 
chains but not for type 2 chain isomers [5,11]. The 
&signal for the internal galactosamine ispresent at 
4.50 and 4.56 ppm (Jr.2 = 8.1 Hz) for the two 
derivatives, respectively. The sharp signals having 
a small coupling constant present at 4.95 ppm (Jl,z 
= 3.5 Hz) for the permethylated erivative and at 
5.05 ppm (Jr.2 = 2.8 Hz) for the reduced derivative 
originate from an internal cr-galactose residue and 
are in accordance with the spectra of 
globotetraosylceramide 191. The two P-signals for 
the remai~ng galactose and the glucose linked to 
ceramide are found at 4.30 and 4.21 ppm for the 
permethylated erivative and at 4.36 and 4.21 ppm 
for the reduced derivative. 
The gas chromatogram of the products obtained 
by degradation of the native glycolipid fraction 
revealed 5 peaks of acetylated alditols correspon- 
ding to fucose (logo), galactose (43%), glucose 
(21%), galactosamine (22Yo), and glucosamine 
(4%). 
The major degradation products obtained from 
the permethylated glycolipid fraction were iden- 
tified by gas chromato~aphy (fig.4, top) and mass 
spectrometry as the acetates of 2,3,4-trimethylfuci- 
to1 (Fuel +), 2,3,6-trimethylgalactito1(-+4Gall-+), 
2,3,dtrimethylglucitol (-+4Glcl+), 2,4,6-trime- 
thylgalactitol (*3Gall+), 4,6_dimethylgalacti- 
to1 (ZiGall -+), 3,4,6-trimethyl-2-~-methylaceta- 
mido-2-deoxygalactitol (GalNAcl -+) and 4,6- 
dimethyl-2-N-methyl-acetamido-2-deoxygalactitol 
(+3GalNAcl). In addition, minor peaks of 2,3,4,6- 
tetramethylgalactitol (Gal+), 3,6-dimethyl-2-N- 
methylacetamido-2-deoxyglucitol (+4GlcNAcl+) 
and 6-methyl-2-~-methyla~etamido-Z-deoxygluci- 
to1 (Z’$GlcNAcl -+) were present. These peaks 
originate from the minor glycolipid components 
found in the mass spectra. For the permethylated- 
reduced derivative (fig.4, bottom), the amino 
sugars together with -+3Gall+ and z$Gall+ 
have disappeared and instead peaks with retention 
times corresponding to disaccharides are present. 
This is caused by the reduced amide group in posi- 
tion 2 of the amino sugars which stabilizes the 
adjacent glycosidic bond to the next sugar giving 
rise to disaccharides or trisaccharides [5,12,13]. 
The two major peaks were identified as GalNAcl 
+3Gall* and +3GalNAcl -+3Gall+ and 
the minor ones as --+rlGlcNAcl --) 3Gall-+ and 
=4 GlcNAcl-+SGall--+. 
In conclusion, the structural studies of the hep- 
taglycosyl~er~ide fraction have shown one major 
glycolipid component with the structure 
GalNActvl-+3Ga1(2+ l~Fuc~1-+3GalNAc@l-+3 
Gala1 -+4Gal,&1-+4Glq?l-+ lceramide. The cera- 
mide part was made up of both 18 : 1 dihydroxy- 
and 18 : 0 trihydroxy long chain bases in combina- 
tion with 16 : O-24 : 0 non-hydroxy and 22 : O-24 : 0 
hydroxy fatty acids. The total amount of this com- 
ponent in the kidney was estimated to 16 p/g per g 
dry tissue weight. 
ceramide part was made up of both 18: 1 
Table 1 
Blood group A activity of the heptaglycosylceramide fraction isoIated from 
human kidney 
Antigen Dilution of anti-A antiserum 
1:0 I:1 I:2 I:4 1:8 1:16 I:32 1:64 
Saline control 4+ 4+ 4-F 4+ 4+ 3-t l+ - 
Kidney glycolipid 3+ - - - - - - - 
k-1 glycolipid 3+ 1+ - - - - - - 
The test was performed as an inhibition of hemagglutination of human 
blood group A red cells by anti-A antiserum [14]. The glycolipids were 
incorporated in liposomes (cholesterol 25 pg, hydrated lecithin 50 pg. 
glycolipid 50 ,ug). 4 + , complete agglutination; - , no agglutination 
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This glycolipid fraction had an identical blood 
group A activity as a pure blood group A hex- 
aglycosylceramide based on a type 1 chain, when 
tested against a polyclonal anti-A antiserum (table 
1). It also reacted with a mouse monoclonal anti-A 
antiserum when tested by immunostaining on the 
thin-layer plate (not shown). 
4. DISCUSSION 
The extension of globotetraosylceramide to 
blood group H and A structures represents a new 
type of core saccharide based H and A glycolipid 
antigen in human tissues in addition to the type 1 
and type 2 carbohydrate chains. A similar type of 
saccharide having the H and A terminals linked 
pl-+3 to galactosamine has been identified in 
oligosaccharides liberated from human ovarial cyst 
glycoproteins [20,21]. This type of saccharide was 
referred to as a type 3 carbohydrate chain [21]. 
The blood group H hexaglycosylceramide has 
been found in human meconium [19], and 
teratocarcinoma cells [22]. It was also present in 
the kidneys in small amounts as seen by mass spec- 
trometry (see section 3). It has recently been 
isolated from human 0 erythrocytes [23]. The A 
heptaglycosylceramide was isolated from human 
Ai erythrocytes but was found to be absent in A2 
erythrocytes (S. Hakomori, personal communica- 
tion). These new blood group H and A glycolipid 
structures are interesting examples of an earlier 
unknown interaction between the blood group P 
and ABO systems in adult human tissues. The 
biosynthetic pathway for these components is cur- 
rently under investigation (to be published). 
This novel A glycolipid makes up about half of 
the glycolipid based blood group A antigens pre- 
sent in human A kidneys in contrast to 
erythrocytes where it is only a very minor com- 
pound compared with other A glycolipids (S. 
Hakomori, personal communication). The cellular 
localization of this A antigen in the kidney and its 
role as transplantation antigen in blood group in- 
compatible kidney transplantation (A2 kidneys to 
0 recipients [24]) is interesting to know. This may 
now be elucidated by use of monoclonal antibodies 
against these structures and patient sera in com- 
bination with immunohistology and immunostain- 
ing of glycolipids on the thin-layer plate [ 15,161. 
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